Cambridge, UK - 15th September 2017
Nuformix is delighted to announce that Levrett plc, a Company formed to acquire a target company in the pharmaceutical and biotechnology sector, has entered into a conditional agreement to acquire the entire issued share capital of Nuformix Limited.
Nuformix Chief Executive Officer Dr Dan Gooding said: “The Nuformix team is delighted to reach agreement on the Acquisition. We are proud of our intellectual property portfolio and believe that our two lead cocrystal programmes offer great commercial and therapeutic promise. We see considerable benefits in becoming a listed company and the funds raised through this placing will facilitate the clinical development of NXP001 and NXP002. Cocrystal technology allows us to uniquely and robustly protect, enable and differentiate the resulting products. We’ll continue to add toour IP portfolio and pre-clinical validation also funded by the placing will support future entries to the Nuformix pipeline.”
For full announcement see: levrett.com